Previous 10 | Next 10 |
Revenue of $2.3 million up 132% over prior year Gross margin of 73% up 500 basis points over prior year Q1 cash used in operations decreased 14% to $2.1 million Conference call begins at 4:30 p.m. Eastern time today Myomo, Inc. (NYSE American: MYO) (...
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial re...
Thomas Jefferson University Successfully Controls MyoPro Directly from Brain Implant Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering f...
Myomo develops, manufactures, and sells a wearable medical device for stroke patients that lost control or strength in their arms. Myomo's recent quarter and future growth prospects look bright in part because they received the Medicare Certification. They are overhauling their ma...
Myomo, Inc. (MYO) Q4 2020 Earnings Conference Call March 10, 2021 4:30 PM ET Company Participants Kim Golodetz - LHA Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital Kyle Bauser - Colliers Securities Jim Sidoti...
Myomo (MYO): Q4 Non-GAAP EPS of -$0.37 beats by $0.18; GAAP EPS of -$0.36 beats by $0.13.Revenue of $3.79M (+149.3% Y/Y) beats by $0.44M.101 units were delivered to patients including 97 recognized as revenue, a 126% increase.Backlog, which represents insurance authorizations received but not...
Record Q4 2020 revenue of $3.8 million up 149% over prior year Full year 2020 revenue of $7.6 million up 98% vs. 2019 Q4 gross margin of 73% up 100 basis points over prior year Q4 cash used in operations of $1.2 million lowest since June 2017 IPO Confer...
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul R. Gudonis, Myomo’s...
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial re...
Follows approval by several other major German providers Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders a...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 17:00:05 ET Scott Henry from Industrial Alliance Securities issued a price target of $5.75 for MYO on 2024-07-10 15:33:00. The adjusted price target was set to $5.75. At the time of the announcement, MYO was trading at $4.97. The overall price target consensus...
2024-07-10 16:15:02 ET Alliance Global Partners analyst issues BUY recommendation for MYO on July 10, 2024 03:33PM ET. The previous analyst recommendation was Buy. MYO was trading at $4.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-07-09 10:30:11 ET Lake Street analyst issues BUY recommendation for MYO on July 9, 2024 08:45AM ET. The previous analyst recommendation was Buy. MYO was trading at $4.07 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...